Figure 7

Over-expression of eve is sufficient to down regulate expression of slowpoke and nAcRα-96Aa. (A,B) In situ analysis shows that aCC/RP2 express both slo (a) and nAcRα-96Aa (b). A portion of the ventral nerve cord from embryonic stage 15 is shown. Scale bar = 5 μm. (C) Pan-neuronal expression of UAS-eve is sufficient to significantly decrease the level of slowpoke (slo) mRNA in isolated CNS from late stage 17 embryos (5.15 ± 0.4-fold decrease, n = 5, **p ≤ 0.01). By comparison, this same manipulation resulted in no significant change in shal mRNA (0.2 ± 0.1-fold decrease, n = 5, p > 0.05). (D) Pan-neuronal expression of UAS-eve results in a significant decrease in the abundance of nAcRα-96Aa mRNA (2.78 ± 0.7-fold decrease, n = 5, *p ≤ 0.05), but no change in mRNA for nAcRβ-64B (0.1 ± 0.3-fold decrease).